Prospective Study of Classification and Activity Assessment of Psoriatic Arthritis Based on Power Doppler (PD) Ultrasonography (PDUS)
Recruiting · NCT06730334 · Observational (researchers observe without assigning treatment) · Lead sponsor: Nanjing Medical University
View the official record on ClinicalTrials.gov →What this trial is about
Psoriatic arthritis (PsA) is a complex inflammatory disease with heterogeneous clinical features, which complicates psoriasis in 30% of patients. PsA involves multiple tissues and clinical domains including skins and nails as well as arthritis, spondylitis, enthesitis, and dactylitis. Power Doppler (PD) ultrasonography (PDUS) is a sensitive non-invasive imaging technology used to assess disease activity and treatment response in PsA. This is a prospective, observational, open-label study to investigate disease activity, therapeutic response and bone destruction based on ultrasonography findings in patients with PsA.
Who can take part
Inclusion criteria
- PsA patients as defined by CASPAR criteria
- Patients must be able to comply with the visit schedule, treatment plan, laboratory tests and other study procedures
- Patients must be given informed consent
Exclusion criteria
- History of other arthritis within the last 12 months
- Concomitant disease with acute or chronic infectious diseases
- Pregnancy or laction
- Poorly tolerated with venipuncture required for blood sampling during the study
Where it is running
2 locations listed.
- Department of Rheumatology and Immunology, Jiangsu Province Hospital - Nanjing, Jiangsu, China
- Jiangsu Province Hospital - Nanjing, Jiangsu, China